1
|
Yamada R, Sato M, Kawabata M, Nakatsuka H,
Nakamura K and Takashima S: Hepatic artery embolization in 120
patients with unresectable hepatoma. Radiology. 148:397–401. 1983.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Arata S, Tanaka K, Okazaki H, Kondo M,
Morimoto M, Saito S, Numata K, Nakamura S and Sekihara H: Risk
factors for recurrence of large HCC in patients treated by combined
TAE and PEI. Hepatogastroenterology. 48:480–485. 2001.PubMed/NCBI
|
3
|
A comparison of lipiodol chemoembolization
and conservative treatment for unresectable hepatocellular
carcinoma. Groupe d'Etude et de Traitement du Carcinome
Hépatocellulaire. N Engl J Med. 332:1256–1261. 1995. View Article : Google Scholar : PubMed/NCBI
|
4
|
WHO, . Handbook for reporting the results
of cancer treatment. Offset Publication No. 48. World Health
Organization; Geneva: pp. 34–35. 1979
|
5
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin Onco.
12:649–655. 198:
|
6
|
Cancer Therapy Evaluation Program.
http://ctep.cancer.gov/reporting/ctc.htmlFebruary
25–2010
|
7
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the radiation therapy oncology group (RTOG) and the
European organization for research and treatment of cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pavy JJ, Denekamp J, Letschert J,
Littbrand B, Mornex F, Bernier J, Gonzales-Gonzales D, Horiot JC,
Bolla M and Bartelink H: EORTC Late Effects Working Group. Late
effects toxicity scoring: The SOMA scale. Int J Radiat Oncol Biol
Phys. 31:1043–1047. 1995. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lawrence TS, Robertson JM, Anscher MS,
Jirtle RL, Ensminger WD and Fajardo LF: Hepatic toxicity resulting
from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1237–1248.
1995. View Article : Google Scholar : PubMed/NCBI
|
10
|
Shetty K, Rybicki L and Carey WD: The
Child-Pugh classification as a prognostic indicator for survival in
primary sclerosing cholangitis. Hepatology. 5:1049–1053. 1997.
View Article : Google Scholar
|
11
|
Glouse ME, Stokes KR, Kruskal JB, Perry
LJ, Stuart KE and Nasser IA: Chemoembolization for hepatocellular
carcinoma: Epinephrine followed by a doxorubicin-ethiodized oil
emulsion and gelatin sponge powder. J Vasc Interv Radiol.
4:717–725. 1993. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nakai M, Sato M, Kawai N, Minamiguchi H,
Masuda M, Tanihata H, Takeuchi T, Terada M and Kishi K:
Hepatocellular carcinoma: Involvement of the internal mammary
artery. Radiology. 219:147–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
13
|
Seong J, Park HC, Han KH, Lee DY, Lee JT,
Chon CY, Moon YM and Suh CO: Local radiotherapy for unresectable
hepatocellular carcinom a patients who failed with transcatheter
arterial chemoembolization. Int J Radia Oncol Biol Phys.
47:1331–1335. 2000. View Article : Google Scholar
|
14
|
Xiong LS, Dong ZX, Liang JG, Long C and Li
YY: Three-dimensional conformal radiotherapy(3-DCRT) for 69 cases
of massive primary liver cancer. Chin Oncol. 16:478–479. 2006.
|
15
|
Dang YZ, Huang SG, Lu WL, Wu FW and Wang
QY: Curative effect of stereotactic body radiotherapy on hepatic
hilar carcinoma. Mol Clin Oncol. 2:1135–1138. 2014.PubMed/NCBI
|
16
|
Park C, Papiez L, Zhang S, Story M and
Timmerman RD: Universal survival curve and single fraction
equivalent dose: Useful tool in understanding potency of ablative
radiotherapy. Int J Radiat Oncol Biol Phys. 70:847–852. 2008.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Fletcher GH: Clinical dose-response curve
of subclinical aggregates of epithelial cells. J Radiol Electrol
Med Nucl. 53:201–206. 1972.PubMed/NCBI
|